PRODUCTS OFFERED
Available from QED Biosciences:
1. Polyclonal Antibody to active RIPK2 (anti-phosphotyrosine 474 RIPK2) useful for both animal and human tissue sections to monitor active RIPK2 at https://www.qedbio.com/product/ripk2/ (please see publication #4 for use)
2. RIPK2 kinase inhibitor at https://www.qedbio.com/product/ripk2-inhibitor-1/ (please see publication #1 for use), a potent inhibitor against active RIPK2 and an anti-inflammatory to reduce NFkB activation and lung and colonic inflammation at 1-5 ug/g body weight IP injection every 4 days.
Coming Soon (Fall 2023)
1. Monoclonal Antibody to RASSF1A, the most epigenetically silenced tumor suppressor in cancer (Please see publication #3 for a review)
2. Monoclonal Antibody to active RIPK2 (anti-phosphoserine 174/176/178 RIPK2)
3. Monoclonal Antibody to active RIPK2 (anti-phosphotyrosine 474 RIPK2)
PUBLICATIONS
1. Salla. M et al. Identification and Characterization of Novel Receptor Interacting Serine/threonine‐Protein Kinase 2 (RIPK2) Inhibitors Using Structural Similarity Analysis. JPET 2018
This publication documents the identification and biological characterization of our RIPK2 inhibitors.
This publication documents the identification and biological characterization of our RIPK2 inhibitors.
| salla_et_al_jpet_2018.pdf |
2. Said. S et al. RASSF1A modulation of autophagy during DSS-induced inflammation (in submission).
This publication documents the in vivo identification of RIPK2 as a marker for intestinal inflammation, the use of RIPK1 inhibitors to alleviate intestinal inflammation in a colitis-model and the molecular mechanism of how RIPK2 can drive NFkB activation and how RASSF1A can restrict the function of RIPK2.
3. Volodko, N. et al. RASSF tumor suppressor gene family: Biological functions and regulation.
FEBS Letters 2015
The review article summarizes our current understanding of the role for the tumor suppressor gene family, RASSF1A. Several members of this family are epigenetically silence in several cancers
| volodko_et_al_febs_letters_2014.pdf |
4. Zare et al. RIPK2: New Elements in Modulation Inflammatory Breast Cancer Pathogenesis. Cancers 2018.
https://www.mdpi.com/2072-6694/10/6/184
This article provided immunological evidence for the presence of active RIPK2 in inflammatory breast cancer.
https://www.mdpi.com/2072-6694/10/6/184
This article provided immunological evidence for the presence of active RIPK2 in inflammatory breast cancer.
